Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC004240 | Panoply™ Human DFNA5 Knockdown Stable Cell Line | Inquiry |
| CSC-SC004240 | Panoply™ Human DFNA5 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT1478 | Human DFNA5 Knockout Cell Line-HeLa | Inquiry |
| CLKO-1328 | DFNA5 KO Cell Lysate-HeLa | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD04801Z | Human DFNA5 adenoviral particles | Inquiry |
| LV10631L | human DFNA5 (NM_001127454) lentivirus particles | Inquiry |
| LV10632L | human DFNA5 (NM_004403) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH277305 | shRNA set against Mouse DFNA5 (NM_018769.3) | Inquiry |
| SHH277301 | shRNA set against Human DFNA5 (NM_004403.2) | Inquiry |
| SHW000447 | shRNA set against Chicken DFNA5 (NM_001006361) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCS407801 | Human DFNA5 ORF Clone (BC019689) | Inquiry |
| CDFH005007 | Human DFNA5 cDNA Clone(NM_001127453.1) | Inquiry |
| CDFH005008 | Human DFNA5 cDNA Clone(NM_001127454.1) | Inquiry |
| MiUTR1H-02790 | DFNA5 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-03820 | DFNA5 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-10241 | DFNA5 miRNA 3'UTR clone | Inquiry |
| MiUTR3H-10242 | DFNA5 miRNA 3'UTR clone | Inquiry |
| CDCB161922 | Chicken DFNA5 ORF Clone (NM_001006361) | Inquiry |
| CDCB186772 | Rabbit DFNA5 ORF clone (XM_008261546.1) | Inquiry |
| CDCR055078 | Human DFNA5 ORF clone (NM_001127454.1) | Inquiry |
| CDCR253394 | Mouse Dfna5 ORF Clone(NM_018769.3) | Inquiry |
| CDCR287800 | Human DFNA5 ORF Clone(NM_004403.2) | Inquiry |
| CDCR348693 | Human DFNA5 ORF Clone(NM_001127453.1) | Inquiry |
| CDCS407802 | Human DFNA5 ORF Clone (BC125065) | Inquiry |
| CDCS407803 | Human DFNA5 ORF Clone (BC099911) | Inquiry |
Cleavage of gasdermin proteins produces pore-forming amino-terminal fragments that lead to inflammatory cell death (heat exhaustion). Gasdermin E (GSDME, also known as DFNA5), which is mutated in familial age-associated hearing loss, can be catabolised by caspase 3, which converts non-inflammatory apoptosis to pyoptosis in GSDME-expressing cells.
DFNA5 Gene Linked to Hearing Loss
Mutations in the DFNA5 gene cause autosomal dominant nonsyndromic hereditary hearing loss (NSHHL). To date, four different DFNA5 gene mutations causing hearing loss have been reported. DFNA5 was first identified as the gene responsible for autosomal dominant hearing loss (HL). The different mutations that have been identified have highly specific gain-of-function effects, with skipping of exon 8 leading to hearing loss. Subsequent reports have shown that the gene is associated with different types of cancer.
DFNA5 may act as a tumor suppressor
DFNA5 expression is suppressed in many cancers, and reduced levels of DFNA5 have been associated with reduced survival in breast cancer patients, suggesting that DFNA5 may be a tumor suppressor. There is evidence that GSDME acts as a tumor suppressor (including epigenetic inactivation of GSDME by promoter DNA methylation in many cancer lines and primary cancers; GSDME inhibits colony formation and cell proliferation in gastric, melanoma and colorectal cancers, and invasiveness in breast cancers; and breast cancers with hypo-expressed GSDME have a lower five-year survival and higher metastasis rates). GSDME-expressing breast cancers have lower five-year survival and higher metastatic rates). Inflammatory cell death is induced in GSDME-expressing cancers subjected to intrinsic stress (hypoxia or endoplasmic reticulum stress) or extrinsic challenge (chemotherapy, radiotherapy, or cytotoxic cell attack). or cytotoxic lymphocyte attack) activates caspase 3, with significant effects on the tumor microenvironment, immune cell recruitment and function, and tumor growth.
Mechanisms by which DFNA5 exerts tumor-suppressive effects
DFNA5 expression enhances phagocytosis of tumor cells by tumor-associated macrophages and increases the number and function of tumor-infiltrating natural killer lymphocytes and CD8+ T lymphocytes. Killer cell granzyme B also directly cleaves DFNA5 at the same site as caspase 3, thereby activating caspase-independent thermal apoptosis in target cells. Non-cleavable or pore-deficient DFNA5 proteins are not tumor inhibitory. Therefore, tumor DFNA5 acts as a tumor suppressor by activating pyoptosis and enhancing anti-tumor immunity.
References: